Yahoo Finance’s Anjalee Khemlani breaks down the latest on coronavirus with Alexis Christoforous and Brian Sozzi.

Video Transcript

BRIAN SOZZI: This week, some notable economists got behind a letter from the Economic Security Project and the Justice Collaborative advocacy group calling on policymakers to keep stimulus payments coming until the economy is fully recovered. House Speaker Nancy Pelosi also said that developing a coronavirus relief bill will cost at least $1.3 trillion and is arguing it still might not be enough.

Anjalee Khemlani is here to break all things down in this week-- in this week's coronavirus pandemic. Anjalee, it's been quite the week.

ANJALEE KHEMLANI: It really has, Brian. And, yes, to your point about Nancy Pelosi's comments there saying it's still not enough and we're still looking at, you know, largely an exponential growth in cases. We're consistently breaking our records day over day for daily cases. Just yesterday with 73,000 cases, new per day, and that is more than the previous record of 72,000 on July 10. So just in a week's time span, we're hitting yet another record, unfortunately.

And this goes into that point of, you know, even more uncertainty at a time where the virus was supposed to be sort of lowering its impact and we were supposed to be able to get a handle on it overall in the US. We're getting headlines about testing being consistently delayed even more than it was and in more states. And that is a large part of it is that there are more states impacted right now than previously when it was just the New York, New Jersey area, Brian.

ALEXIS CHRISTOFOROUS: Anjalee, there's a lot of anticipation around this Oxford data concerning the AstraZeneca COVID vaccine. What are you hearing?

ANJALEE KHEMLANI: That's right. Hearing that it's supposed to be positive. Still waits to be seen. It's supposed to come out on Monday, so hopefully we'll get a clearer sense of where that stands. Right now, we know that Moderna is that front-runner in the US. We're waiting to hear about the Oxford vaccine, which has a lot of interest and a lot of deals already in place globally. So that really answers the question of what happens with the rest of the world in terms of access to a vaccine as well as China having their front-runner, which is already being utilized in the military.

So a lot of movement this month when it comes to the vaccine race. We're waiting to see how this all pans out. By the end of the month, we're definitely going to be hearing a lot more.

BRIAN SOZZI: And, Anjalee, on the vaccine front, it has been quite the week for Moderna.

ANJALEE KHEMLANI: It has. We did hear some good news, you know, earlier about their data and what that impact is going to be. We're also waiting until the start of phase three to get any information about whether or not it can be effective. We know that there has been a lot of support from the federal government in developing this vaccine trial as well as what will eventually happen when it comes to production. So definitely looking at all of that and waiting to see how that all pans out.

BRIAN SOZZI: All right, Anjalee Khemlani, good to see you.